Pharmaceutical Technology on MSN

Gilead acquires first TCE asset with $2.2bn Ouro Medicines buyout

This atypical deal structure will see Gilead collaborate with Galapagos to develop gamgertamig for the treatment of B-cell ...
The Pharma Letter

Dupixent approved in Japan as first targeted medicine for bullous pemphigoid

The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent ...

Regeneron Pharmaceuticals, Inc.: Dupixent (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)

Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo ...

Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid

Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoidApproval in ...

Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)

Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained ...